CELG News and Press, Celgene Corporation From 08/19/19

CELG stock is currently on a good run of good news in 2019 after a few years of bad news from Celgene Corporation (NASDAQ:CELG). In May, the company secured US Food and Drug Administration approval for a combination of Rituxan and Revlimid, which is a second-line follicular lymphoma and...

This article is a continuation of a monthly series highlighting the top net payout yield (NPY) stocks that was started back in June 2012 and explained in August 2012 . The series highlights the best stocks for the upcoming month, utilized in part to make investment decisions for the IB Ass...

Bristol-Myers Squibb ( BMY ) is under considerable pressure, the stock has declined by more than 25% from its highs of the year due to generalized negativity towards the drug manufacturing sector and the uncertainty produced by the Celgene ( CELG ) acquisition. On the other hand, the busin...

Health Catalyst (NASDAQ: HCAT ) initiated with Buy rating and $49 (16% upside) price target at Goldman Sachs. Initiated with Buy rating and $53 price target at SunTrust, Outperform with a $50 a target at Evercore ISI, Outperform with a $55 target at SVB Leerink, Outperform at William Blair a...

Four of my favorite times of the trading year are the days that Form 13F filings are released. Those filings give all investors and traders a chance to see what the big money is buying, selling or holding. In particular I am interested in the funds that invest largely in M&A stocks. I tr...

INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC ® (fedratinib) for the treatment of adult patients with intermediate-2...

Under Priority Review status, FDA approves Celgene's ( CELG +0.6% ) Inrebic (fedratinib) for the treatment of a bone marrow disorder called intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytopenia) myelofibrosis. More news on: Celgene ...

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb's 13F stock portfolio on a quarterly basis. It is based on Third Point's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Dan Loeb's Third Point Portfolio series to get an i...

Daniel Loeb's Third Point hedge fund says it cut its stake in United Technologies ( UTX +1% ), becoming the second activist hedge fund to sell shares following the merger announcement with Raytheon. More news on: United Technologies Corporation, Tradeweb Markets Inc., American Express ...